For laboratory and research use only. Not for human or animal consumption. Sold to qualified researchers and licensed laboratories.
HomeShopNootropics & Neuro › PE-22-28
PE-22-28 10 mg research peptide vial with lot PE2-2609-X label
Nootropics & Neuro · SKU P22-10

PE-22-28 10 mg

Spadin analogue studied for TREK-1 channel blockade.

$ 70 per 10 mg vial · free shipping over $300

In stock · ships same day on orders before 2pm ET

Purity (HPLC-UV)≥99.0% on lot PE2-2609-X
IdentityConfirmed by LC-MS
FormLyophilized powder, sealed vial
Endotoxin< 0.5 EU/mg (LAL)
Storage-20°C sealed · 2-8°C reconstituted
CAS number1801959-12-5
Molecular formulaC35H55N11O9
Molecular weight773.9 g/mol
Residues7
Volume pricing, applied automatically in the cart
QuantityPer unitYou save
3 to 4 units$65.107%
5 to 9 units$62.3011%
10+ units$58.8016%

Verify lot PE2-2609-X in the COA library · This month's lot report

Ships same day on orders before 2pm ET. For laboratory research use only. Not for human or animal consumption.

Frequently bought together

Supplies researchers add to this order

Reconstitution kit
Reconstitution kitKit · $49.99

What is PE-22-28?

PE-22-28 is a truncated analogue of spadin, itself a fragment of the sortilin propeptide, and is studied as a blocker of the TREK-1 potassium channel. TREK-1 blockade is of interest because the channel has been linked to mood regulation in knockout models. Pepstral supplies it as a lyophilized powder for in-vitro laboratory research only.

What is PE-22-28 studied for?

  • TREK-1 channel blockade assays
  • Spadin fragment comparisons
  • Electrophysiology studies
  • Mood-related signalling research

All applications above are in-vitro or preclinical research contexts. PE-22-28 is sold for laboratory research only and is not for human or animal use.

What does the certificate for lot PE2-2609-X show?

Every lot of PE-22-28 is tested by an independent US laboratory before it is listed. The report for lot PE2-2609-X is in the COA library and the lot number printed on the vial matches it. The current results:

TestMethodLot PE2-2609-X result
IdentityLC-MSMatches the calculated mass for the sequence
PurityHPLC-UV, 220 nm99.0%
Net peptide contentAmino acid analysisStated per vial on the certificate
EndotoxinLAL, chromogenic< 0.5 EU/mg
SterilityUSP <71>Pass

How is PE-22-28 handled and stored?

Sealed vials are stored at -20°C away from light and keep for 24 months. To reconstitute, add bacteriostatic water slowly down the inside wall of the vial and swirl until clear; never shake. Once in solution, keep at 2 to 8°C and use within the 28-day window on the certificate. The reconstitution guide covers volumes and syringe units and the concentration table gives the numbers for this vial.

Frequently asked questions

What is TREK-1?

A two-pore-domain potassium channel. Its deletion produces a depression-resistant phenotype in mouse models, which is what makes blockers of it interesting.

How does PE-22-28 relate to spadin?

It is a shorter fragment of the same propeptide sequence, retaining the channel-blocking region.

Is PE-22-28 for human use?

No. Every product on this site is sold for in-vitro laboratory research only and is not for human or animal consumption, diagnostic or therapeutic use.

Related

More in Nootropics & Neuro

Semax 10 mg research peptide vial

Semax

Nootropics & Neuro · 10 mg
≥99.0% purity · COA lot SEM-2609-X
from$65
Selank 10 mg research peptide vial

Selank

Nootropics & Neuro · 10 mg
≥99.0% purity · COA lot SEL-2609-Y
from$65
P-21 5 mg research peptide vial

P-21

Nootropics & Neuro · 5 mg
≥99.0% purity · COA lot P21-2609-X
from$120
Dihexa 5 mg research peptide vial

Dihexa

Nootropics & Neuro · 5 mg
≥99.0% purity · COA lot DIH-2609-X
from$140Sold out
COA on every lotPublished before listing
≥99% purityHPLC and LC-MS verified
Same-day shippingOrders before 2pm ET
Secure checkout256-bit encrypted
USA-basedSynthesized and shipped domestically
Discreet packagingPlain box, no product names

Restock alerts and new lot reports, by email

One email when a new certificate is published, when a sold-out compound is back, or when a new compound is added. About twice a month, nothing else.